Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

被引：0
|
作者：
Rik Vandenberghe
Juha O. Rinne
Mercè Boada
Sadao Katayama
Philip Scheltens
Bruno Vellas
Michael Tuchman
Achim Gass
Jochen B. Fiebach
Derek Hill
Kasia Lobello
David Li
Tom McRae
Prisca Lucas
Iona Evans
Kevin Booth
Gerald Luscan
Bradley T. Wyman
Lisa Hua
Lingfeng Yang
H. Robert Brashear
Ronald S. Black
机构：
[1] Alzheimer Research Centre KU Leuven,University Hospitals Leuven, Department of Neurosciences
[2] University of Turku and Turku University Hospital,Turku PET Centre and Division of Clinical Neurosciences
[3] Fundació ACE,Graduate School of Biomedical Sciences
[4] Barcelona Alzheimer Treatment and Research Center,Alzheimercentrum VUmc, Neurology
[5] Hiroshima University,Department of Neurology, University Hospital Mannheim
[6] VU University Medical Center,undefined
[7] CHU Toulouse,undefined
[8] Gérontopôle,undefined
[9] Palm Beach Neurological Center,undefined
[10] University Medical Centre Mannheim,undefined
[11] Center for Stroke Research Berlin (CSB),undefined
[12] Charité Universitätsmedizin Berlin,undefined
[13] IXICO Ltd.,undefined
[14] The London Bioscience Innovation Centre,undefined
[15] Pfizer Inc.,undefined
[16] Pfizer Inc.,undefined
[17] Pfizer Global Research and Development (PGRD),undefined
[18] Pfizer Ltd.,undefined
[19] Pfizer Inc.,undefined
[20] Janssen Alzheimer Immunotherapy Research & Development,undefined
[21] LLC,undefined
来源：
Alzheimer's Research & Therapy | / 8卷
关键词：
Alzheimer’s disease; Bapineuzumab; Immunotherapy; Amyloid β; Clinical trial; ARIA-E; Vasogenic edema;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
    Vandenberghe, Rik
    Rinne, Juha O.
    Boada, Merce
    Katayama, Sadao
    Scheltens, Philip
    Vellas, Bruno
    Tuchman, Michael
    Gass, Achim
    Fiebach, Jochen B.
    Hill, Derek
    Lobello, Kasia
    Li, David
    McRae, Tom
    Lucas, Prisca
    Evans, Iona
    Booth, Kevin
    Luscan, Gerald
    Wyman, Bradley T.
    Hua, Lisa
    Yang, Lingfeng
    Brashear, H. Robert
    Black, Ronald S.
    ALZHEIMERS RESEARCH & THERAPY, 2016, 8
  • [2] Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
    Abdelrahman Ibrahim Abushouk
    Ahmed Elmaraezy
    Amro Aglan
    Reham Salama
    Samar Fouda
    Rana Fouda
    Ammar M. AlSafadi
    BMC Neurology, 17
  • [3] Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials
    Abushouk, Abdelrahman Ibrahim
    Elmaraezy, Ahmed
    Aglan, Amro
    Salama, Reham
    Fouda, Samar
    Fouda, Rana
    AlSafadi, Ammar M.
    BMC NEUROLOGY, 2017, 17
  • [4] Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease
    Novak, Gerald
    Fox, Nick
    Clegg, Shona
    Nielsen, Casper
    Einstein, Steven
    Lu, Yuan
    Tudor, Iulia Cristina
    Gregg, Keith
    Di, Jianing
    Collins, Peter
    Wyman, Bradley T.
    Yuen, Eric
    Grundman, Michael
    Brashear, H. Robert
    Liu, Enchi
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (04) : 1123 - 1134
  • [5] Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients
    Ketter, Nzeera
    Brashear, H. Robert
    Bogert, Jennifer
    Di, Jianing
    Miaux, Yves
    Gass, Achim
    Purcell, Derk D.
    Barkhof, Frederik
    Arrighi, H. Michael
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (02) : 557 - 573
  • [6] Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
    Doody, Rachelle S.
    Thomas, Ronald G.
    Farlow, Martin
    Iwatsubo, Takeshi
    Vellas, Bruno
    Joffe, Steven
    Kieburtz, Karl
    Raman, Rema
    Sun, Xiaoying
    Aisen, Paul S.
    Siemers, Eric
    Liu-Seifert, Hong
    Mohs, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (04): : 311 - 321
  • [7] Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab
    Russu, Alberto
    Samtani, Mahesh N.
    Xu, Steven
    Adedokun, Omoniyi J.
    Lu, Ming
    Ito, Kaori
    Corrigan, Brian
    Raje, Sangeeta
    Liu, Enchi
    Brashear, H. Robert
    Styren, Scot
    Hu, Chuanpu
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (02) : 535 - 546
  • [8] Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Gao, Yaqi
    Guo, Jing
    Zhang, Fang
    Li, Yanfang
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2024, 27 (01) : 40 - 47
  • [9] Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
    Adrian Ivanoiu
    Jérémie Pariente
    Kevin Booth
    Kasia Lobello
    Gerald Luscan
    Lisa Hua
    Prisca Lucas
    Scot Styren
    Lingfeng Yang
    David Li
    Ronald S. Black
    H. Robert Brashear
    Thomas McRae
    Alzheimer's Research & Therapy, 8
  • [10] Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies
    Ivanoiu, Adrian
    Pariente, Jeremie
    Booth, Kevin
    Lobello, Kasia
    Luscan, Gerald
    Hua, Lisa
    Lucas, Prisca
    Styren, Scot
    Yang, Lingfeng
    Li, David
    Black, Ronald S.
    Brashear, H. Robert
    McRae, Thomas
    ALZHEIMERS RESEARCH & THERAPY, 2016, 8
12345